cerca CERCA
Martedì 19 Ottobre 2021
Aggiornato: 15:31
Temi caldi


deCODE genetics - New study on inheritance and fetal growth

REYKJAVIK, Iceland, July 19, 2021 /PRNewswire/ -- In a paper published in Nature genetics today, Scientists from deCODE genetics, a fully owned subsidiary of Amgen, report sequence variants that associate with birth weight and demonstrate how these variants affect birth weight through both the maternal and fetal genomes. Although birth weight is associated with a range of health outcomes, it is debated how much these relationships are through the fetal genome or affected by the intrauterine envir...

Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy

BAGSVÆRD, Denmark, Nov. 5, 2020 /PRNewswire/ -- Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3 phase 3a trial investigated the efficacy and safety of once-weekly semaglutide 2.4 mg after 68 weeks of treatment compared with placebo both as adjunct to IBT, which consisted of 30 counselling sessions...

ora in
Prima pagina
in Evidenza